This study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell leukemia and lymphoma. Specifically, the study will evaluate the safety and feasibility of CD4CAR T-cells. Funding Source - FDA OOPD
T-cell Lymphoma, T-cell Leukemia
This study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell leukemia and lymphoma. Specifically, the study will evaluate the safety and feasibility of CD4CAR T-cells. Funding Source - FDA OOPD
CD4CAR for CD4+ Leukemia and Lymphoma
-
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States, 33136
Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States, 46202
Stony Brook Cancer Center, Stony Brook, New York, United States, 11794
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
12 Years to
ALL
No
Huda Salman,
Huda Salman, MD, PRINCIPAL_INVESTIGATOR, Indiana University
2040-12